SciBase Files FDA 510(k) to Expand Nevisense Use for Non-Melanoma Skin Cancer
SciBase has submitted a 510(k) premarket notification to the U.S. FDA to expand the use of its AI device Nevisense to include non-melanoma skin cancers, aiming to broaden its clinical application beyond melanoma.